Page last updated: 2024-08-23

colforsin and dironyl

colforsin has been researched along with dironyl in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burris, KD; Kikuchi, T; Miwa, T; Mori, T; Stark, A; Tadori, Y; Tottori, K	1
Feenstra, RW; Glennon, JC; Hesselink, MB; Long, SK; McCreary, AC; Reinders, JH; Ronken, E; Van Der Neut, M; Van Scharrenburg, G	1

Other Studies

2 other study(ies) available for colforsin and dironyl

Article	Year
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European journal of pharmacology, 2005, May-16, Volume: 515, Issue:1-3 Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; DNA, Complementary; Dopamine; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Humans; Lisuride; Piperazines; Piperidines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Risperidone; Transfection; Tritium	2005
In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse (New York, N.Y.), 2006, Dec-15, Volume: 60, Issue:8 Topics: Animals; Benzoxazoles; Binding, Competitive; Brain; CHO Cells; Colforsin; Cricetinae; Cyclic AMP; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Lisuride; Male; Molecular Structure; Parkinson Disease; Piperazines; Quinpirole; Radioligand Assay; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Dopamine D3; Recombinant Fusion Proteins; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists	2006

Article

Year

Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.

European journal of pharmacology, 2005, May-16, Volume: 515, Issue:1-3

Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; DNA, Complementary; Dopamine; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Humans; Lisuride; Piperazines; Piperidines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Risperidone; Transfection; Tritium

2005

In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.

Synapse (New York, N.Y.), 2006, Dec-15, Volume: 60, Issue:8

Topics: Animals; Benzoxazoles; Binding, Competitive; Brain; CHO Cells; Colforsin; Cricetinae; Cyclic AMP; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Lisuride; Male; Molecular Structure; Parkinson Disease; Piperazines; Quinpirole; Radioligand Assay; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Dopamine D3; Recombinant Fusion Proteins; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists

2006